A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis

Trial Profile

A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Amiselimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MOMENTUM
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 10 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network, 13781).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top